Fresh health and wellness news from Oklahoma

Provided by AGP

Oklahoma Healthcare Wire: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.

Press releases published on March 2, 2026

Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Altimmune to Participate in Upcoming Investor Conferences
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
uniQure Announces 2025 Financial Results and Provides Recent Company Updates
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
MapLight Therapeutics to Participate in Upcoming Investor Conferences
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
GT Biopharma Reports Full Year 2025 Financial Results

Share us

on your social networks:

Sign up for:

Oklahoma Healthcare Wire

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.